Gliclazide Tablet

GLYNOL potentiates the release and improvement of the dynamics of insulin. It decreases mean fasting blood glucose and postprandial blood glucose in just 2 weeks. 64.2% of patients achieved the target of blood glucose level defined by the American Diabetes Association. Gliclazide stimulates insulin secretion in the long-term, reduces hepatic gluconeogenesis, whereas metformin improves insulin sensitivity.
It is also available in:
GLYNOL-M  Gliclazide 80mg+Metformin500mg